EGFR-mutation-status determination is a mandatory step in the treatment algorithm for patients with advanced non-small-cell lung cancer (NSCLC), highlighting the importance of biomarker-driven targeted therapies in this indication. EGFR tyrosine kinase inhibitors (TKIs)—Tarceva (Roche/ Genentech), Iressa (AstraZeneca), Tagrisso (AstraZeneca), and Gilotrif/Giotrif (Boehringer Ingelheim)—have been the conventional first-line choice of therapy in EGFR-mutation-positive metastatic nonsquamous NSCLC for many years. In 2018, the next-generation EGFR TKI Vizimpro (Pfizer) was approved in the United States for the first-line treatment of patients with EGFR  mutations. The PD-1 inhibitor Opdivo (Bristol-Myers Squibb) for treatment of EGFR-mutation-positive metastatic nonsquamous NSCLC is another option for patients who have progressed on EGFR TKIs. However, resistance to EGFR TKIs and treatment-related adverse events remain key unmet needs in the metastatic setting, generating opportunity for novel therapies to gain an upper hand over the existing drugs in the NSCLC treatment landscape.


  • What are the treatment drivers and goals for EGFR-mutation-positive metastatic nonsquamous NSCLC?
  • How do current therapies, such as Opdivo, perform on key treatment drivers and goals for EGFR-mutation-positive metastatic nonsquamous NSCLC?
  • What are the prevailing areas of unmet need and opportunity in EGFR-mutation-positive metastatic nonsquamous NSCLC?
  • What trade-offs across different clinical attributes and price are acceptable to surveyed oncologists for hypothetical new treatment options in first-line EGFR-mutation-positive metastatic nonsquamous NSCLC?


Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 61 medical oncologists in US and 30 medical oncologists in Europe fielded in March 2019.

Key companies: Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Pfizer, Teva.

Key drugs: Tarceva, Iressa, Gilotrif/Giotrif, Tagrisso, Vizimpro, Avastin (in combination with paclitaxel and carboplatin), Opdivo.

Table of contents

  • Detailed, Expanded Analysis: EGFR-positive metastatic non-squamous NSCLC (US & EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in EGFR-Mutation-Positive Metastatic Nonsquamous NSCLC
      • Key Findings: Unmet Need in EGFR-Mutation-Positive Metastatic Nonsquamous NSCLC and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the EGFR-Mutation-Positive Metastatic Nonsquamous NSCLC and Related Indications Market and Emerging Therapy Insights
        • Opportunity: A Novel Therapy That Can Prolong Overall Survival
        • Opportunity: A New Therapy That Improves Progression-Free Survival and Elicits a More-Durable Response
        • Opportunity: A Novel Agent with Improved Safety and Tolerability to Improve Patients' Quality of Life
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • EGFR-Mutation-Positive Metastatic Nonsquamous NSCLC and Related Indications Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Bibliography

Author(s): Vandana, M.Pharm

Vandana is a Research Associate in the oncology team at Decision Resources Group. Her current work is focused on performing market research in several oncology indications across the major pharmaceutical markets. Prior to joining DRG, she worked as a Business Analyst (Digital marketing) at Iquanti, Bangalore. She has also previously worked as Analyst in WNS, Noida, India. She has worked on multiple client projects involving competitive intelligence, forecasting, pipeline analysis, keywords research and product/company profiling. She has earned her Master's in Pharmacology from DIPSAR, New Delhi, India.

Related Reports

Non-Small-Cell Lung Cancer | Landscape & Forecast | Disease Landscape & Forecast

Non-small-cell lung cancer (NSCLC) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint i...

View Details

Non-Small-Cell Lung Cancer | China In-Depth | China | 2019

MARKET OUTLOOK Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in China. NSCLC has one of th...

View Details

Non-Small-Cell Lung Cancer | Access & Reimbursement | Detailed, Expanded Analysis (EU)

MARKET OUTLOOK Non-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, wh...

View Details

Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | 2018

The treatment landscape for NSCLC continues to evolve at a rapid pace with the additions of new therapies and label expansions of current therapies i...

View Details